Publicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario da Coruña (37)

2023

  1. Renal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort

    European Journal of Hospital Pharmacy, Vol. 30, Núm. 4, pp. 221-226

2022

  1. Discontinuation due to neuropsychiatric adverse events with efavirenz-and dolutegravir-based antiretroviral therapy: a comparative real-life study

    European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 207-211

  2. Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV

    AIDS, Vol. 36, Núm. 5, pp. 691-695

2021

  1. Reply to “Critically ill patients infected with HIV: 15 years of experience”

    Medicina Intensiva

  2. Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure

    Journal of Viral Hepatitis, Vol. 28, Núm. 9, pp. 1319-1324

2020

  1. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients

    European Journal of Hospital Pharmacy, Vol. 27, Núm. 1 e, pp. E41-E47

  2. Hepatitis E 3ra Genotype Infection in People Living With HIV in Spain

    Frontiers in Microbiology, Vol. 11

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

2015

  1. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792

2011

  1. Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/Hepatitis C virus-coinfected patients treated for chronic hepatitis C

    Clinical Infectious Diseases, Vol. 53, Núm. 12, pp. 1291-1295

2009

  1. Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection

    Journal of Viral Hepatitis, Vol. 16, Núm. 4, pp. 249-258

  2. Saquinavir exposure in HIV-infected patients with chronic viral hepatitis

    Journal of Antimicrobial Chemotherapy, Vol. 63, Núm. 5, pp. 992-997

  3. The Spanish HIV BioBank: A model of cooperative HIV research

    Retrovirology, Vol. 6

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

2007

  1. Impacto de la reducción de dosis de estavudina en su perfil de eficacia/seguridad en pacientes con infección por el virus de la inmunodeficiencia humana inmunológica y virológicamente estables

    Medicina Clinica, Vol. 129, Núm. 10, pp. 361-365

2006

  1. "Liver toxicity and metabolic alterations associated with nevirapine therapy and the influence of hepatitis C virus infection"

    Nutrition and Metabolic Disorders in HIV Infection, Vol. 5, Núm. 1, pp. 891-897

  2. Combinaciones a dosis fijas y coinfección por el VIH y el virus de la hepatitis B o C

    Enfermedades Infecciosas y Microbiologia Clinica Monografias, Vol. 5, Núm. 4, pp. 64-71

  3. Paciente con VIH, fiebre y lesiones cutáneas

    Revista Clinica Espanola, Vol. 206, Núm. 6, pp. 291-292

2005

  1. 67 year old male, chronic alcholism and hydropic descompensation

    Revista Clinica Espanola

  2. Detection of HCV-RNA in saliva of HIV-HCV coinfected patients

    AIDS Research and Human Retroviruses, Vol. 21, Núm. 12, pp. 1011-1015